Tissue Factor: a validated target for improved solid tumor antibody-drug conjugates – a pipeline review STUTTGART, Germany I August 27, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-Tissue Factor immunotherapeutics in R&D: Pipeline of Tissue Factor-Targeted Immunotherapies. This competitive...

CD38: a Blockbuster sales target under fire by biosuperior and biosmilar antibody competitors – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CD38 immunotherapeutics in R&D: Pipeline of CD38-Targeted Immunotherapies. This competitive...

TROP-2: a Blockbuster target with opportunities for new drug modalities – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-TROP-2 immunotherapeutics in R&D: Pipeline of TROP-2-Targeted Immunotherapies. This competitive intelligence report about...

Nectin-4: a clinically and commercially validated target with limited competition – a pipeline review STUTTGART, Germany I August 26, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-nectin-4 immunotherapeutics in R&D: Pipeline of Nectin-4-Targeted Immunotherapies. This competitive intelligence report about...

CCR8: an attractive immuno-oncology target for antibody therapy – a pipeline review STUTTGART, Germany I August 20, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-CCR8 immunotherapeutics in R&D: Pipeline of CCR8-Targeted Immunotherapies. This competitive intelligence report about CCR8-Targeted Immunotherapies...

EpCAM: conditional activation technologies can make EpCAM a viable target – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-EpCAM immunotherapeutics in R&D: Pipeline of EpCAM-Targeted Immunotherapies. This competitive intelligence report about...

5T4: a delicate target for sophisticated payload delivery – a pipeline review STUTTGART, Germany I August 19, 2025 I La Merie Publishing announced the release of the free report Pipeline of 5T4-Targeted Immunotherapies to showcase its newest service of pipeline reviews. The free report reviews the pipeline of active anti-5T4...

B7-H4: a promising target for effector-enhanced drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-B7-H4 immunotherapeutics in R&D: Pipeline of B7-H4-Targeted Immunotherapies. This competitive intelligence report about B7-H4-Targeted Immunotherapies...

Mesothelin: an old solid tumor target for next generation drug modalities – a pipeline review STUTTGART, Germany I August 18, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-mesothelin immunotherapeutics in R&D: Pipeline of Mesothelin-Targeted Immunotherapies. This competitive intelligence report...

c-Met: a well-suited target for payload delivery by antibodies – a pipeline review STUTTGART, Germany I August 15, 2025 I La Merie Publishing announced the release of its newest product offering reviewing the pipeline of active anti-c-Met immunotherapeutics in R&D: Pipeline of c-Met-Targeted Immunotherapies. This competitive intelligence report about c-Met-Targeted...